The Delaware Chancery Court dismissed Tesaro's anticipatory breach of contract claim against AnaptysBio, affirming that Anaptys did not repudiate their Collaboration Agreement regarding Jemperli. The ruling preserves Anaptys' current royalty rates and rejects Tesaro's request for a royalty reduction. Anaptys alleges Tesaro breached key contract terms, including exclusivity and diligence duties, and is pursuing a trial scheduled for July 14-17, 2026, to resolve these claims and seek reversion rights to Jemperli. This decision supports Anaptys' efforts to protect its royalty stream and contractual rights against Tesaro and GSK.
UBS maintains a neutral rating on GSK ahead of its Q2 results, focusing on CEO Luke Miels' upcoming strategy update. UBS expects little market reaction to the earnings, highlighting concerns over a £4 billion gap between GSK's sales target and foreca...
UBS maintains a neutral rating on GSK ahead of its Q2 results and a strategy update from new CEO Luke Miels, focusing on whether he can deliver GSK's target of over £40 billion in risk-adjusted sales by 2031. UBS forecasts slightly below consensus fo...
